Canaccord Genuity Raises Price target on Nuance Communications (NUAN) Following 4Q

Nuance (NUAN) Business Transition Complete, Now the Rewards Come - Oppenheimer

Nuance Communications (NASDAQ: NUAN) reported revenues of $513.3M, exceeding the Street's estimate of $507.8M. When adjusting for currency headwinds, revenue would have been up 1% YoY. EPS of $0.41 bested the Street's $0.35 estimate on better volumes and higher operating margins of 30.2% vs. the Street's 28% estimate.... More

Nuance Communications (NUAN) Reports 4Q Beat; FBR Capital Raises Price Target to $21

FBR Capital reiterated a Market Perform rating on Nuance Communications (NASDAQ: NUAN), and raised the price target to $21.00 (from $20.00), following the company's 4Q earnings report. Total revenue of $513.3 million beat the Streets $507.8 million estimate and came in at the high end of the company's guidance of between $497 million and $513 million. Pro forma EPS came in at $0.41, beating the Streets $0.35 estimate.

Analyst Daniel Ives commented, "Last night, November... More

Healthcare and Consumer Segments Drive Solid 4Q Results; Needham & Company Reiterates Hold on Nuance Communications (NUAN)

Needham & Company reiterated a Hold rating on Nuance Communications (NASDAQ: NUAN) following the company's 4Q earnings report. Revenue of $513 million and $0.41 EPS were both above consensus of $508 million and $0.35. The Healthcare and Consumer segments drove results, while the Enterprise and Imaging businesses continue to... More

Leerink Boosts PT on Nuance Communications (NUAN) to $21 Following Q4 Results, Strong Outlook

Leerink is raising its price target on Outperform-rated Nuance Communications (Nasdaq: NUAN) from $19 to $21 following Q4 results and solid FY16 guidance issued Monday night.

Analyst Steven Wardell noted positives and negatives from the quarter:

Positives -

After-Hours Movers 11/16: (OCRX) (NUAN) Higher; (URBN) (W) (EQIX) Lower (more...)

Ocera Therapeutics (NASDAQ: OCRX) 38.5% HIGHER; announced positive results from the Company's Phase 1 study of the oral formulation of OCR-002, ornithine phenylacetate, in healthy subjects. OCR-002 exhibited encouraging extended-release properties, demonstrated a desirable pharmacokinetic (PK) profile and was... More

Market Wrap: Marriott Aims to Acquire Peer; Clovis Oncology Slammed on Adverse News; Constellation Bolsters Beer Offerings

End of the Day: S&P 500 up 30.2 to 2,053.19; Dow Jones up 237.8 to 17,486.01; Nasdaq up 56.7 to 4,984.62

Market Brief: Empire State Manufacturing results came in weaker than expected in October.

Marriott moved to acquire Starwood Hotels.

13Fs aplenty out late last week and today.

Clovis Oncology was hit following adverse rociletinib news.

Constellation Brands picks up microbrew.

Pandora scoops up certain Rdio... More

Nuance Communications (NUAN) Issues Q1, FY16 Guidance

Nuance Communications (NASDAQ: NUAN) sees Q116 adjusted EPS of $0.31 - $0.33 and revenue of $486 - $498 million, versus the consensus at $491 million.

The company sees $1.35 - $1.45, versus the Street at $1.38. NUAN also sees FY16 revenue of $1.98 - $2.03 billion, with the consensus at EPS of $0.31 and revenue of $2.01 billion.

Carl Icahn's 13F Shows New Stake in PayPal (PYPL), Maintained Stake in Apple (AAPL), Herbalife (HLF) (more...)

Carl Icahn released his 13F for the quarter ended Sept 30, 2015. Below is a summary:

New Stakes
American International Group, Inc. (NYSE: AIG) new 1,361,326 share position
Freeport-McMoran Cp & Gld (NYSE: FCX) new 100,000,000 share position *
PayPal... More

Nuance Communications (NUAN) Tops Q4 EPS by 6c

Nuance Communications (NASDAQ: NUAN) reported Q4 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $513.3 million versus the consensus estimate of $507.84 million.

Nuance delivered a strong finish to its fiscal year, reporting revenue, EPS, cash flow from... More